GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis with nasal polyps, or CRSwNP.
GSK’s depemokimab and Amgen and AstraZeneca’s Tezspire both met the co-primary endpoints in ...
↧